GERN241220P9000
- 0.00
- 0.000.00%
Geron Newsroom
Barclays Initiates Geron(GERN.US) With Buy Rating, Announces Target Price $9
Geron Q4 Revenue Estimate Raised Above Consensus at Barclays
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Express News | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Geron Corporation Announces Appointment of Joseph Eid, M.d. as Executive Vice President, Research and Development
Geron to Participate in the Stifel 2024 Healthcare Conference
TD Cowen Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $10
Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results
Barclays Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9
Scotiabank Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6
A Quick Look at Today's Ratings for Geron(GERN.US), With a Forecast Between $6 to $10
Scotiabank Keeps Their Buy Rating on Geron (GERN)
Geron Corporation's Q3 2024: Strong RYTELO Launch and Financial Growth
10-Q: Q3 2024 Earnings Report
Robust Market Potential and Strategic Positioning Drive Optimistic Buy Rating for Geron
Geron Secures up to $375 Million in Funding With Royalty Pharma, Pharmakon Advisors
Geron Corporation (GERN) Q3 2024 Earnings Call Transcript
Express News | Geron Corporation : H.c. Wainwright Raises Target Price to $9 From $8
Geron Secures $250M Funding and Strong Q3 Sales